Bridged ring compound, pharmaceutical composition thereof and use thereof
By providing novel bridged ring compounds, the problem of poor compliance of existing TNF-α inhibitors with large molecules is solved, achieving high efficiency of TNF-α inhibitory activity and low cardiotoxicity of small molecule compounds, and improving the bioavailability and metabolic stability of the compounds.
WO2026145577A1PCT designated stage Publication Date: 2026-07-09ETERN THERAPEUTICS (WUXI) CO LTD
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- ETERN THERAPEUTICS (WUXI) CO LTD
- Filing Date
- 2025-12-30
- Publication Date
- 2026-07-09
AI Technical Summary
Technical Problem
Existing TNF-α inhibitors are mainly macromolecules, which have problems such as poor patient compliance, high production costs, and inconvenient storage and transportation. There is a lack of application of small molecule compounds.
Method used
A novel bridged ring compound is provided, which exhibits good TNF-α inhibitory activity, high exposure, excellent absolute bioavailability and low cardiotoxicity. The specific structure consists of a compound of formula (III) and its pharmaceutically acceptable salt, isotope substitute, solvate or solvate of salt.
Benefits of technology
This study achieved TNF-α inhibitory activity of small molecule compounds, improved the bioavailability and hepatic microsomal metabolic stability of the compounds, and reduced cardiotoxicity.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN2025147378_09072026_PF_FP_ABST
Abstract
Disclosed in the present invention are a bridged ring compound, a pharmaceutical composition thereof and the use thereof. Specifically, disclosed in the present invention is a compound as shown in formula (III), a pharmaceutically acceptable salt thereof, an isotopically substituted substance thereof, a solvate thereof, or a solvate of the pharmaceutically acceptable salt thereof. The compound of the present invention has good biological activities and / or pharmacokinetic properties.
Need to check novelty before this filing date? Find Prior Art